1 – 6 of 6
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
(
- Contribution to journal › Article
- 2010
-
Mark
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study
(
- Contribution to journal › Article
- 2009
-
Mark
Changes in prandial glucagon levels after 2 years treatment with vildagliptin or glimepiride
2009) 45th Annual Meeting of the European-Association-for-the-Study-of-Diabetes In Diabetologia 52(Suppl 1). p.798-798(
- Contribution to journal › Published meeting abstract
-
Mark
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
(
- Contribution to journal › Article
- 2008
-
Mark
The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat
2008) 44th EASD Annual Meeting of the European Association for the Study of Diabetes In Diabetologia 51(S1). p.318-318(
- Contribution to journal › Published meeting abstract
-
Mark
Liraglutide, a once-daily human GLP-1 analogue, in type 2 diabetes provides similar glycaemic control with reduced body weight compared with glimepiride when added to metformin
2008) 44th EASD Annual Meeting of the European Association for the Study of Diabetes In Diabetologia 51(S1). p.358-358(
- Contribution to journal › Published meeting abstract